[Dementia with Lewy bodies].

By E. Mori. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2000

931 citations recorded by the source corpus.

Dementia with Lewy bodies (DLB), the second most frequent cause of primary degenerative dementias following Alzheimer's disease, has been increasingly recognized since the proposal of the consensus name and clinical diagnostic criteria. Although DLB overlaps in clinical, pathological, and genetic features with Alzheimer's disease and Parkinson's disease, DLB should be understood as an entity with the essential feature of the presence of Lewy bodies in the brain stem and cerebral cortex. From the clinical point of view, DLB is characterized by the presence of progressive dementia without severe memory disorders at the early stage, with significant cognitive fluctuations, well-formed recurrent visual hallucinations, and spontaneous Parkinsonism. This article reviews recent clinical and research findings, including our own, to facilitate clinical recognition of DLB. In addition to the supportive features described in the consortium clinical diagnostic criteria for DLB such as falls and great sensitivity to neuroleptic drugs, our studies found other frequent disorders including disproportionately severe visuoconstructive and visuoperceptual disturbances, transitory alterations in consciousness with reduplication phenomena, misidentification delusions, and non-aphasic misnamings. Neuroimaging features include relatively preserved hippocampal volume on MRI and occipital involvement on metabolic and blood flow imagings. The correct diagnosis of DLB is important to administer adequate treatment, to avoid adverse effects with neuroleptic drugs, and to establish precise prognosis. The present summary of the clinical features is hopefully helpful for clinical diagnosis of DLB. From a therapeutic point of view, cholinesterase inhibitors seemingly show some efficacy in the treatment of cognitive alterations. Further research would result in advances in diagnostic methods and therapeutic approaches in the near future.

Subfields: Neurology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/86ec9c8332a4a0b7551a891a4fae149e728854a0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Pharmacology

In Psychiatry and Mental health

Citations in the corpus

Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications (2004, background): “However, there has long been contention as to whether Parkinson’s disease and dementia with Lewy bodies represent a continuum of one disorder or are distinct disorders.(9) Paradoxically, our data may support both hypotheses as overexpression of a normal, wild-type -synuclein is sufficient to cause a”
Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. (2007, background): “As we have noted previously (Boeve et al., 2003c, 2004; Boeve, 2004; Boeve and Saper, 2006), RBD is analogous to the syndrome of mild cognitive impairment (MCI).”
Parkinson's disease and parkinsonism: neuropathology. (2012, background): “PD dementia is distinguished from dementia with Lewy bodies (McKeith et al. 2004), in which dementia is an early and prominent clinical feature.”